Reversible Encepahlopathy Induced by Ifosfamide with Brain Imaging.

MRI brain damage chemotherapy reversible encephalopathy induced by ifosfamide

Journal

Global pediatric health
ISSN: 2333-794X
Titre abrégé: Glob Pediatr Health
Pays: United States
ID NLM: 101670224

Informations de publication

Date de publication:
2021
Historique:
received: 12 05 2021
accepted: 15 06 2021
entrez: 5 8 2021
pubmed: 6 8 2021
medline: 6 8 2021
Statut: epublish

Résumé

Chemotherapy may be responsible for central and/or peripheral neurotoxicity. These neurological complications are frequent but little known. Some molecules are more providers, responsible for acute or late complications, sometimes not reversible. Some manifestations such as acute encephalopathy and acute reversible encephalopathy are increasingly understood. We report here a case of acute ifosfamide-induced encephalopathy (EII) with brain damage resolved after discontinuation of this treatment in a 13-years-old child.

Identifiants

pubmed: 34350307
doi: 10.1177/2333794X211030415
pii: 10.1177_2333794X211030415
pmc: PMC8287358
doi:

Types de publication

Case Reports

Langues

eng

Pagination

2333794X211030415

Informations de copyright

© The Author(s) 2021.

Déclaration de conflit d'intérêts

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Références

Cancer Chemother Pharmacol. 2019 Nov;84(5):1097-1105
pubmed: 31502115
Pediatr Blood Cancer. 2016 Feb;63(2):372-3
pubmed: 26397980
Am J Clin Oncol. 2005 Jun;28(3):277-80
pubmed: 15923801
Drug Saf. 2008;31(11):989-96
pubmed: 18840018
J Pediatr Hematol Oncol. 2005 Nov;27(11):582-9
pubmed: 16282887
J Clin Neurophysiol. 2019 Mar;36(2):150-154
pubmed: 30694943
Bull Cancer. 2012 Sep;99(9):851-63
pubmed: 22961349
J Pharmacol Pharmacother. 2017 Jan-Mar;8(1):38-40
pubmed: 28405136
Lancet. 2009 Nov 7;374(9701):1639-51
pubmed: 19897130
Clin Oncol (R Coll Radiol). 2007 Mar;19(2):108-14
pubmed: 17355105
J Formos Med Assoc. 2016 Sep;115(9):744-51
pubmed: 26302952
Pediatr Blood Cancer. 2019 Dec;66(12):e27996
pubmed: 31535455

Auteurs

Daoud Ali Mohamed (D)

Pediatric Radiology Department, Children's Hospital of Rabat, University Hospital of Ibn Sina Rabat, Rabat, Morocco.

Arthur Semedo (A)

Pediatric Radiology Department, Children's Hospital of Rabat, University Hospital of Ibn Sina Rabat, Rabat, Morocco.

Boris Adeyemi (B)

Pediatric Radiology Department, Children's Hospital of Rabat, University Hospital of Ibn Sina Rabat, Rabat, Morocco.

Leila Hessissen (L)

Hematology-Oncology Department, Children's Hospital of Rabat, University Hospital of Ibn Sina Rabat, Rabat, Morocco.

Maria El Kababri (M)

Hematology-Oncology Department, Children's Hospital of Rabat, University Hospital of Ibn Sina Rabat, Rabat, Morocco.

Nazik Allali (N)

Pediatric Radiology Department, Children's Hospital of Rabat, University Hospital of Ibn Sina Rabat, Rabat, Morocco.

Latifa Chat (L)

Pediatric Radiology Department, Children's Hospital of Rabat, University Hospital of Ibn Sina Rabat, Rabat, Morocco.

Siham El Haddad (S)

Pediatric Radiology Department, Children's Hospital of Rabat, University Hospital of Ibn Sina Rabat, Rabat, Morocco.

Classifications MeSH